Observational Post-authorization Studies Carboplatin, Paclitaxel and Bevacizumab
This is a pharmacogenomic study with carboplatin, paclitaxel and bevacizumab as first line therapy in patients with non-squamous advanced non-small cell lung cancer.
Nonsquamous Nonsmall Cell Neoplasm of Lung
DRUG: paclitaxel, carboplatin and bevacizumab
Correlation between angiogenesis markers and progression free survival., 1 year
Overal survival, 3 year|Survival at 12 and 24 months, 12-24 months|Objective response, 24 months|Duration of response, 24 months|Treatment security, 24 months
This is a observational study prospectively followed post-authorization.